DexCom Inc. (NASDAQ:DXCM)’s share price fell 0.3% on Friday . The stock traded as low as $77.29 and last traded at $78.00, with a volume of 488,341 shares traded. The stock had previously closed at $78.21.

Several research firms have recently weighed in on DXCM. Canaccord Genuity reiterated a “buy” rating on shares of DexCom in a research note on Thursday, April 28th. Zacks Investment Research lowered shares of DexCom from a “hold” rating to a “sell” rating in a research report on Tuesday, June 28th. Robert W. Baird restated a “hold” rating on shares of DexCom in a research report on Monday, May 16th. Oppenheimer Holdings Inc. restated a “hold” rating on shares of DexCom in a research report on Thursday, April 28th. Finally, Wedbush restated an “outperform” rating and issued a $112.00 price objective on shares of DexCom in a research report on Wednesday, June 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $94.09.

The firm’s market cap is $6.58 billion. The firm has a 50 day moving average price of $72.45 and a 200-day moving average price of $68.63.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, April 27th. The medical device company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by $0.03. The business earned $116.20 million during the quarter, compared to the consensus estimate of $110.37 million. During the same quarter in the prior year, the business earned ($0.17) earnings per share. The business’s revenue was up 59.6% compared to the same quarter last year. Equities research analysts expect that DexCom Inc. will post ($0.37) EPS for the current year.

In other DexCom news, SVP Jeffrey Moy sold 6,866 shares of the business’s stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $71.00, for a total transaction of $487,486.00. Following the transaction, the senior vice president now owns 76,333 shares of the company’s stock, valued at $5,419,643. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John Lister sold 3,704 shares of the business’s stock in a transaction on Tuesday, April 12th. The stock was sold at an average price of $65.78, for a total value of $243,649.12. Following the transaction, the insider now directly owns 73,014 shares in the company, valued at approximately $4,802,860.92. The disclosure for this sale can be found here.

Other institutional investors have made changes to their positions in the company. Russell Frank Co raised its position in shares of DexCom by 12.0% in the fourth quarter. Russell Frank Co now owns 205,160 shares of the medical device company’s stock valued at $16,897,000 after buying an additional 21,900 shares during the period. State Board of Administration of Florida Retirement System raised its position in shares of DexCom by 2.3% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 90,342 shares of the medical device company’s stock valued at $7,399,000 after buying an additional 2,029 shares during the period. California State Teachers Retirement System raised its position in shares of DexCom by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 146,946 shares of the medical device company’s stock valued at $12,035,000 after buying an additional 2,320 shares during the period. Swiss National Bank raised its position in shares of DexCom by 0.9% in the fourth quarter. Swiss National Bank now owns 105,600 shares of the medical device company’s stock valued at $8,649,000 after buying an additional 900 shares during the period. Finally, Rhumbline Advisers raised its position in shares of DexCom by 0.5% in the fourth quarter. Rhumbline Advisers now owns 88,844 shares of the medical device company’s stock valued at $7,276,000 after buying an additional 480 shares during the period.

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.